Somatostatin Analogs Market Size
| Study Period | 2019 - 2030 |
| Market Size (2025) | USD 7.05 Billion |
| Market Size (2030) | USD 9.08 Billion |
| CAGR (2025 - 2030) | 5.20% |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players*Disclaimer: Major Players sorted in no particular order |
Somatostatin Analogs Market Analysis
The Somatostatin Analogs Market size is estimated at USD 7.05 billion in 2025, and is expected to reach USD 9.08 billion by 2030, at a CAGR of 5.2% during the forecast period (2025-2030).
The rising incidence of hormone-related disorders, such as acromegaly and neuroendocrine tumors, is driving the demand for somatostatin analogs as a therapeutic option. Improved awareness about hormone-related disorders and better diagnostic capabilities lead to increased identification of patients who could benefit from somatostatin analog therapy.
Improved awareness about hormone-related disorders and better diagnostic capabilities lead to increased identification of patients who could benefit from somatostatin analog therapy. A study published in the Endocrine Practice in May 2022 reflected that patients with thyrotropinoma are mostly treated with surgery, but in most cases, a cure is not achieved. However, doses of somatostatin analog gave effective results. This positive outcome could lead to an increased demand for somatostatin analogs among healthcare providers and patients. Hence, it may drive the market growth during the forecast period.
Studies like STOPNET, evaluating the feasibility of discontinuing continuous somatostatin analog therapy post-peptide radionuclide therapy, may lead to a shift in treatment protocols. If successful, this could reduce the long-term reliance on somatostatin analogs, impacting market demand and hindering market growth.
Somatostatin Analogs Market Trends
Acromegaly is Expected to Dominate the Somatostatin Analogs Market
Acromegaly is expected to dominate the somatostatin analogs market during the forecast period. It is a hormonal disorder wherein the pituitary gland produces more growth hormone during adulthood. The rising prevalence of acromegaly, increasing awareness regarding this health condition, and the availability of effective treatments are propelling the segment's growth. For instance, according to a study published by Statpearl in NCBI in February 2023, acromegaly has a worldwide prevalence of about 4,600 per million population, with about 116.9 new cases per million per year, and its incidence is increasing further.
Moreover, the rising incidence of acromegaly globally, coupled with the lack of effective treatments, is driving the demand for innovative therapeutic options, such as somatostatin analogs. The increasing prevalence of acromegaly and the need for better disease management strategies have led pharmaceutical companies to invest in research and development of new somatostatin analogs for improved treatment outcomes. In March 2024, Crinetics Pharmaceuticals Inc. announced the positive results of phase 3 studies that evaluated the efficacy and safety of oral, once-daily investigational paltusotine for the treatment of acromegaly.
Hence, the rising incidence of acromegaly worldwide and the approval and launch of new drugs for treating this health condition are expected to drive the segment's growth during the forecast period.
North America is Expected to Dominate the Somatostatin Analogs Market
North America is at the forefront of growth in the market studied and is also an important revenue contributor in the global arena. The rising prevalence of neuroendocrine carcinoma and acromegaly, the presence of key players, and the rising number of government initiatives are the major factors contributing to the growth of the market studied in North America. For instance, as per the data published by the University of Texas MD Anderson Cancer Center in February 2024, though being a rare disease, it is estimated that more than 12,000 people are found to be affected by neuroendocrine tumors every year in the United States.
Additionally, growing awareness about acromegaly and neuroendocrine tumors, coupled with improved diagnostic techniques, is leading to early detection and treatment initiation, boosting the demand for somatostatin analogs in both the United States and Canada. Moreover, international pharmaceutical companies are developing new drugs to treat different conditions, such as acromegaly, with somatostatin analogs in the United States. For instance, Camurus AB, in December 2023, submitted a new drug application to the US Food and Drug Administration for OclaizTM (CAM2029), the company’s investigational, once-monthly octreotide subcutaneous depot injection for the treatment of patients with acromegaly.
In conclusion, the increasing patient population base, key product launches, and the presence of a wide number of drug developers are some of the factors driving the growth of the somatostatin analogs market in North America.
Somatostatin Analogs Industry Overview
The somatostatin analogs market is fragmented and competitive. It consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the key players include Novartis AG, Sun Pharmaceutical Industries Ltd, Midatech Pharma PLC, Ipsen Pharma, Chiasma Inc., Peptron Inc., Crinetics Pharmaceuticals, Dauntless Pharmaceuticals, Camurus AB, and Teva Pharmaceuticals Inc.
Somatostatin Analogs Market Leaders
-
Novartis AG
-
Sun Pharmaceutical Industries Ltd
-
Midatech Pharma PLC
-
Ipsen Pharma
-
Chiasma, Inc
- *Disclaimer: Major Players sorted in no particular order
Somatostatin Analogs Market News
- May 2024: Cipla Ltd received approval from the US Food and Drug Administration to market its generic lanreotide injection in multiple strengths to treat acromegaly in the United States.
- March 2022: Ipsen announced that the company invested in a new state-of-the-art electronic autoinjector for Somatuline Autogel and Somatuline Depot (which contains lanreotide) to deliver further innovation in the class and improve patient administration and injection experience.
Somatostatin Analogs Industry Segmentation
As per the scope of the report, somatostatin analogs are synthetic compounds that mimic the actions of the naturally occurring hormone somatostatin. These analogs bind to somatostatin receptors in various tissues and organs, exerting regulatory effects on hormone secretion, cell growth, and neurotransmission.
The somatostatin analogs market is segmented by type (octreotide, lanreotide, pasireotide, and other types), application (acromegaly, neuroendocrine tumors (NETs), and other applications), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers market sizes and forecasts in terms of value (USD) for all the above segments.
| By Type | Octreotide | ||
| Lanreotide | |||
| Pasireotide | |||
| Other Types | |||
| By Application | Acromegaly | ||
| Neuroendocrine Tumors (NETs) | |||
| Other Applications | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
| Octreotide |
| Lanreotide |
| Pasireotide |
| Other Types |
| Acromegaly |
| Neuroendocrine Tumors (NETs) |
| Other Applications |
| North America | United States |
| Canada | |
| Mexico | |
| Europe | Germany |
| United Kingdom | |
| France | |
| Italy | |
| Spain | |
| Rest of Europe | |
| Asia-Pacific | China |
| Japan | |
| India | |
| Australia | |
| South Korea | |
| Rest of Asia-Pacific | |
| Middle East and Africa | GCC |
| South Africa | |
| Rest of Middle East and Africa | |
| South America | Brazil |
| Argentina | |
| Rest of South America |
Somatostatin Analogs Market Research FAQs
How big is the Somatostatin Analogs Market?
The Somatostatin Analogs Market size is expected to reach USD 7.05 billion in 2025 and grow at a CAGR of 5.20% to reach USD 9.08 billion by 2030.
What is the current Somatostatin Analogs Market size?
In 2025, the Somatostatin Analogs Market size is expected to reach USD 7.05 billion.
Who are the key players in Somatostatin Analogs Market?
Novartis AG, Sun Pharmaceutical Industries Ltd, Midatech Pharma PLC, Ipsen Pharma and Chiasma, Inc are the major companies operating in the Somatostatin Analogs Market.
Which is the fastest growing region in Somatostatin Analogs Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Somatostatin Analogs Market?
In 2025, the North America accounts for the largest market share in Somatostatin Analogs Market.
What years does this Somatostatin Analogs Market cover, and what was the market size in 2024?
In 2024, the Somatostatin Analogs Market size was estimated at USD 6.68 billion. The report covers the Somatostatin Analogs Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Somatostatin Analogs Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Somatostatin Analogs Industry Report
Statistics for the 2025 Somatostatin Analogs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Somatostatin Analogs analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
